Compare BioNano Genomics Inc (BNGO) vs Consolidated Edison, Inc. (ED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Consolidated Edison, Inc. — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while Consolidated Edison, Inc. trades at $107.32 (market cap $39.76B). The key difference: Consolidated Edison, Inc. is far larger — about 2910.7× BioNano Genomics Inc's market cap, and Consolidated Edison, Inc. pays a 3.27% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | ED | |
|---|---|---|
Market Cap | $13.66M | $39.76B |
Sector | Health | Utilities |
52-Week High | $4.92 | $115.46 |
52-Week Low | $1.06 | $95.37 |
Enterprise Value | $16.26M | $66.61B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Consolidated Edison (ED) trades at $107.33, up 0.97% on the day, slightly above the consensus price target of $103.25. The stock shows a mixed technical picture with bearish moving averages but neutral oscillators, while fundamentals are stable with a P/E of 17.68, net income margin of 12.53%, and consistent dividends. Recent Q2 2026 earnings beat estimates with EPS of $0.83 versus $0.756 expected, though Q1 2026 missed expectations.
Outlook is cautious due to analyst sentiment favoring Hold (62.96%) and bearish technical signals, but the utility's regulated operations and mid-8% rate base growth support steady returns. Risks include high debt levels and interest rate sensitivity, while opportunities lie in grid upgrades for AI-driven power demand. The stock offers a defensive profile with a reliable dividend yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →
